Phathom Pharmaceuticals (PHAT) Competitors $11.64 +0.59 (+5.34%) Closing price 04:00 PM EasternExtended Trading$12.00 +0.36 (+3.09%) As of 05:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PHAT vs. NAMS, VKTX, AMRX, CNTA, XENE, CGON, QURE, RARE, APLS, and IMVTShould you be buying Phathom Pharmaceuticals stock or one of its competitors? The main competitors of Phathom Pharmaceuticals include NewAmsterdam Pharma (NAMS), Viking Therapeutics (VKTX), Amneal Pharmaceuticals (AMRX), Centessa Pharmaceuticals (CNTA), Xenon Pharmaceuticals (XENE), CG Oncology (CGON), uniQure (QURE), Ultragenyx Pharmaceutical (RARE), Apellis Pharmaceuticals (APLS), and Immunovant (IMVT). These companies are all part of the "pharmaceutical products" industry. Phathom Pharmaceuticals vs. Its Competitors NewAmsterdam Pharma Viking Therapeutics Amneal Pharmaceuticals Centessa Pharmaceuticals Xenon Pharmaceuticals CG Oncology uniQure Ultragenyx Pharmaceutical Apellis Pharmaceuticals Immunovant NewAmsterdam Pharma (NASDAQ:NAMS) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends, media sentiment and earnings. Do insiders & institutionals believe in NAMS or PHAT? 89.9% of NewAmsterdam Pharma shares are owned by institutional investors. Comparatively, 99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. 20.8% of NewAmsterdam Pharma shares are owned by insiders. Comparatively, 23.0% of Phathom Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Is NAMS or PHAT more profitable? NewAmsterdam Pharma has a net margin of -259.07% compared to Phathom Pharmaceuticals' net margin of -289.51%. Phathom Pharmaceuticals' return on equity of 0.00% beat NewAmsterdam Pharma's return on equity.Company Net Margins Return on Equity Return on Assets NewAmsterdam Pharma-259.07% -27.27% -25.00% Phathom Pharmaceuticals -289.51%N/A -90.40% Which has higher earnings and valuation, NAMS or PHAT? NewAmsterdam Pharma has higher earnings, but lower revenue than Phathom Pharmaceuticals. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNewAmsterdam Pharma$45.56M81.60-$241.60M-$1.62-20.38Phathom Pharmaceuticals$55.25M14.95-$334.33M-$4.73-2.46 Which has more risk & volatility, NAMS or PHAT? NewAmsterdam Pharma has a beta of 0.02, suggesting that its stock price is 98% less volatile than the S&P 500. Comparatively, Phathom Pharmaceuticals has a beta of 0.43, suggesting that its stock price is 57% less volatile than the S&P 500. Does the media favor NAMS or PHAT? In the previous week, Phathom Pharmaceuticals had 2 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 6 mentions for Phathom Pharmaceuticals and 4 mentions for NewAmsterdam Pharma. NewAmsterdam Pharma's average media sentiment score of 0.87 beat Phathom Pharmaceuticals' score of 0.44 indicating that NewAmsterdam Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NewAmsterdam Pharma 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Phathom Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer NAMS or PHAT? NewAmsterdam Pharma currently has a consensus target price of $42.00, indicating a potential upside of 27.23%. Phathom Pharmaceuticals has a consensus target price of $17.50, indicating a potential upside of 50.34%. Given Phathom Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Phathom Pharmaceuticals is more favorable than NewAmsterdam Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NewAmsterdam Pharma 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.70Phathom Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.71 SummaryPhathom Pharmaceuticals beats NewAmsterdam Pharma on 10 of the 17 factors compared between the two stocks. Get Phathom Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PHAT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PHAT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PHAT vs. The Competition Export to ExcelMetricPhathom PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$783.93M$3.37B$6.14B$10.65BDividend YieldN/A2.29%5.66%4.70%P/E Ratio-2.4621.3485.8427.65Price / Sales14.95470.58621.60138.35Price / CashN/A47.1938.3262.20Price / Book-3.1410.4313.066.79Net Income-$334.33M-$52.40M$3.30B$275.88M7 Day Performance-1.52%6.36%4.81%2.64%1 Month Performance-9.70%16.14%9.99%9.13%1 Year Performance-26.10%33.90%85.28%35.89% Phathom Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PHATPhathom Pharmaceuticals2.3958 of 5 stars$11.64+5.3%$17.50+50.3%-32.9%$783.93M$55.25M-2.46110Analyst ForecastNAMSNewAmsterdam Pharma3.1125 of 5 stars$32.48+5.9%$42.00+29.3%+85.2%$3.45B$45.56M-20.054Analyst ForecastHigh Trading VolumeVKTXViking Therapeutics3.9837 of 5 stars$32.28+8.6%$86.42+167.7%-51.5%$3.34BN/A-21.1020Analyst ForecastGap UpAMRXAmneal Pharmaceuticals2.8651 of 5 stars$10.55+1.5%$12.00+13.7%+21.0%$3.26B$2.85B1,056.068,100Analyst ForecastCNTACentessa Pharmaceuticals3.0006 of 5 stars$23.00-1.0%$32.38+40.8%+38.7%$3.11B$6.85M-12.85200Analyst ForecastXENEXenon Pharmaceuticals2.8656 of 5 stars$39.55-0.2%$53.30+34.8%-4.3%$3.05B$9.43M-11.14210News CoverageAnalyst ForecastAnalyst RevisionCGONCG Oncology2.1965 of 5 stars$38.13-4.2%$56.55+48.3%+16.9%$3.04B$1.14M-21.5461News CoverageAnalyst ForecastQUREuniQure3.1114 of 5 stars$52.91-3.7%$71.75+35.6%+913.0%$3.01B$27.12M-13.50500Trending NewsAnalyst ForecastAnalyst RevisionRAREUltragenyx Pharmaceutical4.3816 of 5 stars$30.19-3.3%$81.50+170.0%-42.1%$3.01B$610.16M-5.461,294Analyst ForecastAPLSApellis Pharmaceuticals4.0876 of 5 stars$24.36+2.4%$33.29+36.7%-9.1%$3.01B$781.37M-13.38770Analyst ForecastIMVTImmunovant2.1088 of 5 stars$16.55-2.1%$33.20+100.6%-45.7%$2.95BN/A-5.81120 Related Companies and Tools Related Companies NewAmsterdam Pharma Alternatives Viking Therapeutics Alternatives Amneal Pharmaceuticals Alternatives Centessa Pharmaceuticals Alternatives Xenon Pharmaceuticals Alternatives CG Oncology Alternatives uniQure Alternatives Ultragenyx Pharmaceutical Alternatives Apellis Pharmaceuticals Alternatives Immunovant Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PHAT) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Phathom Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Phathom Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
